Skip to content

Safety and efficacy of a human albumin solution with restored structural profile in patients with decompensated cirrhosis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515484-54-00
Acronym
RESTORE
Enrollment
88
Registered
2024-10-30
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated cirrhosis

Brief summary

Primary endpoints of the study will be: - Effective albumin concentration at 1, 3 and 6 months from randomization - Safety of the reHA solution during the 6-month treatment assessed by collecting vital signs, lab parameters and any adverse event, namely: • Percentage of subjects with at least 1 adverse event (AE) or serious adverse event (SAE); • Percentage of subjects with at least 1 Adverse Drug Reaction (ADR); •Total number of AE, SAE and ADR; [truncated text, see protocol for details]

Detailed description

Signals of efficacy will be searched by comparing the following parameters at 1, 3 and 6 months from randomization: Organ function: Liver function: grade of ascites (International Club of Ascites criteria), grade of HE (West Haven classification and Animal Naming Test), bilirubin and albumin serum levels; Renal function: BUN, serum creatinine, electrolytes, eGFR estimated by the CKD-EPI equation;[truncated text, see protocol for details]

Interventions

DRUGRITION Glutatione
DRUGAlbunorm 20% "200 g/l
DRUGsoluzione per infusione"

Sponsors

Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Primary endpoints of the study will be: - Effective albumin concentration at 1, 3 and 6 months from randomization - Safety of the reHA solution during the 6-month treatment assessed by collecting vital signs, lab parameters and any adverse event, namely: • Percentage of subjects with at least 1 adverse event (AE) or serious adverse event (SAE); • Percentage of subjects with at least 1 Adverse Drug Reaction (ADR); •Total number of AE, SAE and ADR; [truncated text, see protocol for details]

Secondary

MeasureTime frame
Signals of efficacy will be searched by comparing the following parameters at 1, 3 and 6 months from randomization: Organ function: Liver function: grade of ascites (International Club of Ascites criteria), grade of HE (West Haven classification and Animal Naming Test), bilirubin and albumin serum levels; Renal function: BUN, serum creatinine, electrolytes, eGFR estimated by the CKD-EPI equation;[truncated text, see protocol for details]

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026